BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23801497)

  • 1. Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.
    Yan B; Lim M; Zhou L; Kuick CH; Leong MY; Yong KJ; Aung L; Salto-Tellez M; Chang KT
    J Clin Pathol; 2013 Nov; 66(11):985-91. PubMed ID: 23801497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib targets in glioblastoma stem cells.
    Junca A; Villalva C; Tachon G; Rivet P; Cortes U; Guilloteau K; Balbous A; Godet J; Wager M; Karayan-Tapon L
    Cancer Med; 2017 Nov; 6(11):2625-2634. PubMed ID: 28960893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
    Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
    Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
    Cui JJ; Tran-Dubé M; Shen H; Nambu M; Kung PP; Pairish M; Jia L; Meng J; Funk L; Botrous I; McTigue M; Grodsky N; Ryan K; Padrique E; Alton G; Timofeevski S; Yamazaki S; Li Q; Zou H; Christensen J; Mroczkowski B; Bender S; Kania RS; Edwards MP
    J Med Chem; 2011 Sep; 54(18):6342-63. PubMed ID: 21812414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition.
    Liu CN; Mathialagan N; Lappin P; Fortner J; Somps C; Seitis G; Johnson TR; Hu W; Matsumoto D
    Toxicol Sci; 2015 Jan; 143(1):116-25. PubMed ID: 25326243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.
    Stutz E; Gautschi O; Fey MF; Gugger M; Tschan MP; Rothschild SI
    Future Oncol; 2014 Feb; 10(2):211-7. PubMed ID: 24490607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
    Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
    Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
    J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
    Yang Y; Wu N; Shen J; Teixido C; Sun X; Lin Z; Qian X; Zou Z; Guan W; Yu L; Rosell R; Liu B; Wei J
    Gastric Cancer; 2016 Jul; 19(3):778-88. PubMed ID: 26404902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
    Le Rhun E; Chamberlain MC; Zairi F; Delmaire C; Idbaih A; Renaud F; Maurage CA; Grégoire V
    CNS Oncol; 2015; 4(6):381-6. PubMed ID: 26498130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.